Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Paul J, Hengeveld"'
Autor:
Paul J. Hengeveld, P. Martijn Kolijn, Jeroen A.A. Demmers, Wouter Doff, Julie M.N. Dubois, Melissa Rijken, Jorn L.J.C. Assmann, Lina van der Straten, Henk Jan Boiten, Kirsten J. Gussinklo, Peter J.M. Valk, Laura M. Faber, Peter E. Westerweel, Arnon P. Kater, Mark-David Levin, Anton W. Langerak
Publikováno v:
HemaSphere, Vol 7, Iss 10, p e951 (2023)
It remains challenging in chronic lymphocytic leukemia (CLL) to distinguish between patients with favorable and unfavorable time-to-first treatment (TTFT). Additionally, the downstream protein correlates of well-known molecular features of CLL are no
Externí odkaz:
https://doaj.org/article/9c7c2aec214047bd85fc59184f7b706f
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Over the past decades, several cytogenetic, immunogenetic and molecular features have emerged that identify patients suffering from CLL with high-risk molecular features. T
Externí odkaz:
https://doaj.org/article/3c5ec6fcf5a847e3b1eca8fd080f8f28
Autor:
P. Martijn Kolijn, Alice F. Muggen, Viktor Ljungström, Andreas Agathangelidis, Ingrid L. M. Wolvers-Tettero, H. Berna Beverloo, Karol Pál, Paul J. Hengeveld, Nikos Darzentas, Rudi W. Hendriks, Jacques J. M. van Dongen, Richard Rosenquist, Anton W. Langerak
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Key processes in the onset and evolution of chronic lymphocytic leukemia (CLL) are thought to include chronic (antigenic) activation of mature B cells through the B cell receptor (BcR), signals from the microenvironment, and acquisition of genetic al
Externí odkaz:
https://doaj.org/article/348023aaa5874eb98b52a2826f636eb1
Autor:
Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L. Downey-Kopyscinski, Geoffrey M. Matthews, Benjamin G. Barwick, Vikas A. Gupta, Daphné Dupéré-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer, Eugen Dhimolea, Olga Dashevsky, Sara Gandolfi, Kazuya Ishiguro, Robin M. Meyers, Jordan G. Bryan, Neekesh V. Dharia, Paul J. Hengeveld, Johanna B. Brüggenthies, Huihui Tang, Andrew J. Aguirre, Quinlan L. Sievers, Benjamin L. Ebert, Brian J. Glassner, Christopher J. Ott, James E. Bradner, Nicholas P. Kwiatkowski, Daniel Auclair, Joan Levy, Jonathan J. Keats, Richard W. J. Groen, Nathanael S. Gray, Aedin C. Culhane, James M. McFarland, Joshua M. Dempster, Jonathan D. Licht, Lawrence H. Boise, William C. Hahn, Francisca Vazquez, Aviad Tsherniak, Constantine S. Mitsiades
Publikováno v:
de Matos Simoes, R, Shirasaki, R, Downey-Kopyscinski, S L, Matthews, G M, Barwick, B G, Gupta, V A, Dupéré-Richer, D, Yamano, S, Hu, Y, Sheffer, M, Dhimolea, E, Dashevsky, O, Gandolfi, S, Ishiguro, K, Meyers, R M, Bryan, J G, Dharia, N V, Hengeveld, P J, Brüggenthies, J B, Tang, H, Aguirre, A J, Sievers, Q L, Ebert, B L, Glassner, B J, Ott, C J, Bradner, J E, Kwiatkowski, N P, Auclair, D, Levy, J, Keats, J J, Groen, R W J, Gray, N S, Culhane, A C, McFarland, J M, Dempster, J M, Licht, J D, Boise, L H, Hahn, W C, Vazquez, F, Tsherniak, A & Mitsiades, C S 2023, ' Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias ', Nature Cancer, vol. 4, no. 5, pp. 754-773 . https://doi.org/10.1038/s43018-023-00550-x
Nature Cancer, 4(5), 754-773. Nature Research
Nature Cancer, 4(5), 754-773. Nature Research
Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic mutations in MM. Instead, these agents targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c38520e5128234e34753590416d0e64
https://doi.org/10.1038/s43018-023-00550-x
https://doi.org/10.1038/s43018-023-00550-x
Autor:
Paul J. Hengeveld, Michèle Y. van der Klift, P. Martijn Kolijn, Frédéric Davi, François G. Kavelaars, Evert de Jonge, Sandra Robrecht, Jorn L. J. C. Assmann, Lina van der Straten, Matthias Ritgen, Peter E. Westerweel, Kirsten Fischer, Valentin Goede, Michael Hallek, Mark-David Levin, Anton W. Langerak
Publikováno v:
Blood, 141(5), 519-528. American Society of Hematology
The sensitivity of conventional techniques for reliable quantification of minimal/measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is limited to MRD 10−4. Measuring MRD −4 could help to further distinguish between patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f5bd5398eaa5ab41346baafa6136627
https://pure.eur.nl/en/publications/c5e32979-91ec-407d-855b-b1641fa666cf
https://pure.eur.nl/en/publications/c5e32979-91ec-407d-855b-b1641fa666cf
Autor:
Paul J. Hengeveld, Y. Emre Ertem, Julie M. N. Dubois, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Ludo M. Evers, Kim Heezen, P. Martijn Kolijn, Olaf R. F. Mook, M. Mahdi Motazacker, Kazem Nasserinejad, S. Kersting, Peter E. Westerweel, Carsten U. Niemann, Arnon P. Kater, Anton W. Langerak, Mark-David Levin
Publikováno v:
Leukemia, 36(7), 1935-1938. Nature Publishing Group
Hengeveld, P J, Ertem, Y E, Dubois, J M N, Mellink, C H M, van der Kevie-Kersemaekers, A-M, Evers, L M, Heezen, K, Kolijn, P M, Mook, O R F, Motazacker, M M, Nasserinejad, K, Kersting, S, Westerweel, P E, Niemann, C U, Kater, A P, Langerak, A W & Levin, M-D 2022, ' Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110 ', Leukemia, vol. 36, no. 7, pp. 1935-1938 . https://doi.org/10.1038/s41375-022-01600-6
Hengeveld, P J, Ertem, Y E, Dubois, J M N, Mellink, C H M, van der Kevie-Kersemaekers, A-M, Evers, L M, Heezen, K, Kolijn, P M, Mook, O R F, Motazacker, M M, Nasserinejad, K, Kersting, S, Westerweel, P E, Niemann, C U, Kater, A P, Langerak, A W & Levin, M-D 2022, ' Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110 ', Leukemia, vol. 36, no. 7, pp. 1935-1938 . https://doi.org/10.1038/s41375-022-01600-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faddf632bed0aa0326c60d56e6fb24a1
https://pure.eur.nl/en/publications/cca58e3c-bfba-46df-b5e8-942d64040987
https://pure.eur.nl/en/publications/cca58e3c-bfba-46df-b5e8-942d64040987
Publikováno v:
Experimental Hematology, 93, 14-24. Elsevier Inc.
B-Cell receptor (BCR) sequencing has been the force driving many recent advances in chronic lymphocytic leukemia (CLL) research. Here, we discuss the general principles, revelations, and applications of reading the BCR immunome in the context of CLL.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7724d78fcc04753f9dcb152e2828dbe9
https://doi.org/10.1016/j.exphem.2020.09.194
https://doi.org/10.1016/j.exphem.2020.09.194
Autor:
Paul J, Hengeveld, Y Emre, Ertem, Julie M N, Dubois, Clemens H M, Mellink, Anne-Marie, van der Kevie-Kersemaekers, Ludo M, Evers, Kim, Heezen, P Martijn, Kolijn, Olaf R F, Mook, M Mahdi, Motazacker, Kazem, Nasserinejad, S, Kersting, Peter E, Westerweel, Carsten U, Niemann, Arnon P, Kater, Anton W, Langerak, Mark-David, Levin
Publikováno v:
Leukemia. 36(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5d871805ee1fd3a775813c05e53695dd
https://pubmed.ncbi.nlm.nih.gov/35585140
https://pubmed.ncbi.nlm.nih.gov/35585140
Autor:
Frederic Davi, Paul J. Hengeveld, Anastasia Chatzidimitriou, P Martijn Kolijn, Richard Rosenquist, Anne de Septenville, Kostas Stamatopoulos, Lesley-Ann Sutton, Silvia Bonfiglio, Anton W. Langerak, Paolo Ghia
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, In press, ⟨10.1038/s41375-020-0923-9⟩
Leukemia, 34(10), 2545-2551. Nature Publishing Group
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, In press, ⟨10.1038/s41375-020-0923-9⟩
Leukemia, 34(10), 2545-2551. Nature Publishing Group
Twenty years after landmark publications, there is a consensus that the somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is an important cornerstone for accurate risk stratification and therapeutic decisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a085965050fb754c9fabdfc3178de85
https://pure.eur.nl/en/publications/f1eec476-46ca-4f44-9ac8-17fb99d6f2f4
https://pure.eur.nl/en/publications/f1eec476-46ca-4f44-9ac8-17fb99d6f2f4
Autor:
Aaram Omar Khader, Peter E. Westerweel, Linda H.A. de Bruin, Eske A. van Baalen, Anton W. Langerak, Eva Jansen, Mark-David Levin, Jurgen A Riedl, Paul J. Hengeveld, Ömer Balak, Nathalie I. Bouwer, Inge G.P. Geelen
Publikováno v:
British Journal of Haematology
British Journal of Haematology, 190(4), E201-E204. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 190(4), E201-E204. Wiley-Blackwell Publishing Ltd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7024a291b810e746c524e3a471a64079
https://pure.eur.nl/en/publications/e5980634-aed3-4d37-a7fd-f06a53961bc3
https://pure.eur.nl/en/publications/e5980634-aed3-4d37-a7fd-f06a53961bc3